Gilead Sciences (NQ:GILD)

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Today 8:00 EDT

Both of these ETFs look the part, but only one is truly the better buy for investors.

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? ↗

Today 5:50 EDT

Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and...

Topics ETFs

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day ↗

October 21, 2026

Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support ↗

October 05, 2026

Via Chartmill

Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup ↗

October 02, 2026

Via Chartmill

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

October 19, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

1 Unprofitable Stock with Exciting Potential and 2 We Find Risky

October 19, 2026

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? ↗

October 18, 2026

The company's recent momentum continues unabated.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

3 Inflated Stocks Walking a Fine Line

October 16, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

October 11, 2026

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Topics ETFs

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH ↗

October 10, 2026

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma ↗

Topics ETFs

October 10, 2026

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...

Topics ETFs

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated...

Topics Artificial Intelligence

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets ↗

October 05, 2026

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB ↗

Topics Artificial Intelligence

October 05, 2026

VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Topics ETFs

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.

Topics ETFs

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK ↗

September 25, 2026

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Topics ETFs

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

Topics ETFs

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Topics ETFs

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Topics ETFs

1 Cash-Producing Stock on Our Buy List and 2 We Find Risky

September 22, 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of...

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig ↗

September 21, 2026

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

September 16, 2026

Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief...

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗

September 15, 2026

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? ↗

Topics Intellectual Property

September 15, 2026

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Topics ETFs

September 15, 2026